Hyperion Therapeutics Priced, Nasdaq: HPTX
Focused on the treatment of orphan diseases of the liver relating to the urea cycle.
Industry: Health Care
First Day Return: +1.1%
HPTX
Focused on the treatment of orphan diseases of the liver relating to the urea cycle.
| IPO Data | |
|---|---|
| IPO Date | 07/25/2012 |
| Offer Price | IPO Intelligence Only |
| Price Range | IPO Intelligence Only |
| Offer Shares (mm) | IPO Intelligence Only |
| Deal Size ($mm) | $50 |
| Lock-Up Date | IPO Intelligence Only |
| Street Research | IPO Intelligence Only |
| Underwriters |
|---|
| IPO Intelligence Only |
| Company Data | |
|---|---|
| Headquarters | South San Francisco, CA, United States |
| Founded | 2006 |
| Employees at IPO | 14 |
| Website www.hyperiontx.com | |
IPO News for Hyperion Therapeutics
Hyperion Therapeutics (HPTX) Performance
